Results 181 to 190 of about 25,780 (241)

Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer.

Lung Cancer, 2022
INTRODUCTION Topotecan is approved as second-line treatment for small cell lung cancer (SCLC). Irinotecan is also frequently used given its more convenient schedule and superior tolerability.
M. Edelman, M. Dvorkin, K. Laktionov, A. Navarro, Ó. Juan-Vidal, V. Kozlov, G. Golden, O. Jordan, C. Deng, Dmitriy Bentsion, C. Chouaid, Hristo Dechev, A. Dowlati, N. Fernández Núñez, O. Ivashchuk, I. Kiladze, Tsira Kortua, N. Leighl, A. Luft, Tamta Makharadze, Y. Min, X. Quantin   +21 more
semanticscholar   +1 more source

Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical cancer: a Neuroendocrine Cervical Tumor Registry (NeCTuR) study.

American Journal of Obstetrics and Gynecology, 2022
BACKGROUND Recurrent high-grade neuroendocrine cervical cancer has a very poor prognosis and limited active treatment options. OBJECTIVE This study aimed to evaluate the efficacy of the 3-drug regimen of topotecan, paclitaxel, and bevacizumab in women ...
M. Frumovitz, G. Chisholm, A. Jhingran, P. Ramalingam, Alejandra Flores-legarreta, P. Bhosale, N. Gonzales, R. Hillman, Gloria Slavo   +8 more
semanticscholar   +1 more source

Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL).

Gynecologic Oncology, 2021
OBJECTIVE The randomized phase 3 CORAIL trial evaluated whether lurbinectedin improved progression-free survival (PFS) compared to pegylated liposomal doxorubicin (PLD) or topotecan in patients with platinum-resistant ovarian cancer.
S. Gaillard, A. Oaknin, I. Ray-Coquard, I. Vergote, G. Scambia, N. Colombo, C. Fernandez, V. Alfaro, C. Kahatt, A. Nieto, A. Zeaiter, M. Aracil, L. Vidal, B. Pardo-Burdalo, Z. Pápai, R. Kristeleit, D. O'Malley, I. Benjamin, P. Pautier, D. Lorusso   +19 more
semanticscholar   +1 more source

Efficacy of topotecan nanoparticles for intravitreal chemotherapy of retinoblastoma.

Experimental Eye Research, 2021
Retinoblastoma (Rb) is the most common intraocular malignancy in children that accounts for approximately 4% of all pediatric malignancies. Since chemotherapy is a widely practiced treatment for Rb, there is a growing interest in developing new and ...
E. Delrish, M. Jabbarvand, Fariba Ghassemi, F. A. Amoli, F. Atyabi, A. Lashay, M. Soleimani, Leila Aghajanpour, R. Dinarvand   +8 more
semanticscholar   +1 more source

Oral delivery of topotecan in polymeric nanoparticles: Lymphatic distribution and pharmacokinetics.

Journal of Controlled Release, 2021
There have been many attempts to formulate a variety of drugs in nano-size formulations. However, biodistribution characteristics of these formulated drugs remain unclear.
Seung-Hyun Jeong, Ji-Hun Jang, Yong-Bok Lee   +2 more
semanticscholar   +1 more source

Dual-response electrochemical electrode for sensitive monitoring of topotecan and mitomycin as anticancer drugs in real samples.

Chemosphere, 2021
This research paper employed an innovative electrochemical electrode to simultaneously determine topotecan (TPT) and mitomycin (MMC) as anticancer agents. For this purpose, a novel nanocomposite was synthesized using a hydrothermal procedure.
M. Mehmandoust, F. Uzcan, M. Soylak, N. Erk   +3 more
semanticscholar   +1 more source

Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study

Pediatric Blood & Cancer, 2020
To assess objective response after two cycles of temozolomide and topotecan (TOTEM) in children with refractory or relapsed miscellaneous extracranial solid and central nervous system (CNS) tumors, including medulloblastoma and primitive neuroectodermal ...
G. Le Teuff, Alicia Castaneda-Heredia, C. Dufour, T. Jaspan, R. Calmon, A. Devos, K. McHugh, P. Leblond, D. Frappaz, I. Aerts, C. Zwaan, S. Ducassou, P. Chastagner, A. Verschuur, N. Corradini, M. Casanova, H. Rubié, R. Riccardi, M. le Deley, G. Vassal, B. Geoerger   +20 more
semanticscholar   +1 more source

Modulation of Intestinal Transport and Absorption of Topotecan, a BCRP Substrate, by Various Pharmaceutical Excipients and Their Inhibitory Mechanisms of BCRP Transporter.

Journal of Pharmacy and Science, 2019
Breast cancer resistance protein transporter (ABCG2/BCRP) is highly expressed on the intestinal epithelial membrane and has a significant impact on the oral absorption of topotecan. In this study, we examined 6 pharmaceutical excipients including BL-9EX,
Kasirawat Sawangrat, Shugo Yamashita, A. Tanaka, Masaki Morishita, K. Kusamori, H. Katsumi, Toshiyasu Sakane, A. Yamamoto   +7 more
semanticscholar   +1 more source

Topotecan

Reactions Weekly, 2016
  +7 more sources

Topotecan

Reactions Weekly, 2002
Ines Mader, Patrizia E. Fürst-Weger, Robert M. Mader, Elisabeth I. Semenitz, Robert Terkola, Sabine M. Wassertheurer   +5 more
  +5 more sources